New combo therapy shows promise for premenopausal breast cancer patients
NCT ID NCT06009627
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the drug darsilide to standard hormone therapy (exemestane and goserelin) can shrink tumors in premenopausal women with HR-positive, HER2-negative breast cancer. The 119 participants had not responded fully to initial chemotherapy. The main goal was to see how many patients had a significant reduction in tumor size before surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jie Ge
Tianjin, Tianjin Municipality, 300000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?